{
  "docId": "019de073-5c75-763a-a0f1-d995dc5da488",
  "docSlug": "01bee26c2c6ee992ec5e01a8e02dc689",
  "documentTitle": "Myovant Sciences | Results Presentation Deck | 34 slides",
  "authorId": "myovant-sciences",
  "authorName": "Myovant Sciences",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 34,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses a timeline-based process diagram to illustrate the clinical trial structure.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-5c75-763a-a0f1-d995dc5da488/11",
  "deckHref": "/decks/019de073-5c75-763a-a0f1-d995dc5da488",
  "deckJsonHref": "/decks/019de073-5c75-763a-a0f1-d995dc5da488.json",
  "deckAnchorHref": "/decks/019de073-5c75-763a-a0f1-d995dc5da488#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.9,
        "x": 0.05,
        "y": 0.4
      },
      "kind": "diagram",
      "text": "Clinical trial flow diagram showing randomization (R 1:1:1, N=1251) into three arms, 24-week initial phase, and 80-week extension.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "73e1f156-e551-483b-a25f-d7f66074a375",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.03,
        "y": 0.28
      },
      "kind": "list",
      "text": "Co-Primary Endpoints: Proportion of women with a reduction from baseline of at least 2.8 points on the NRS for dysmenorrhea; Proportion of women with a reduction from baseline of at least 2.1 points on the NRS for NMPP",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "84350ca3-d0d8-46ec-975b-462fe33a29e0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.95,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "paragraph",
      "text": "Two replicate, 24-week, multinational, double-blind trials involving women with moderate to severe pain associated with endometriosis randomized 1:1:1 to receive once-daily placebo, MYFEMBREE, or delayed MYFEMBREE followed by optional open-label 80-week extension study",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ff44a5a1-f943-4544-a90b-3f6849b121f5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.03,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "NRS = Numerical Rating Scale; NMPP = Non-menstrual Pelvic Pain. (1) In the SPIRIT 1 and 2 studies, women randomized to receive MYFEMBREE were dosed with a once daily relugolix 40 mg tablet plus an over encapsulated tablet of estradiol (E2) 1 mg and norethindrone acetate (NETA) 0.5 mg (relugolix+E2/NETA), which is equivalent to 1 tablet of MYFEMBREE. (2) Relugolix 40 mg monotherapy for 12 weeks followed by MYFEMBREE for 12 weeks.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "172b1c84-b3ec-4508-aacb-f1996832330a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.4,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "Phase 3 SPIRIT Clinical Program",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "211be324-0b51-4c7a-ba0e-9b91b0e41074",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "c989ee9c-0fe5-46db-b221-27497ec80126",
      "evidence": "The diagram uses a timeline-based structure to show study phases and durations.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 16,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "b061a9eb-90da-4016-a0fc-6239c295f0b9",
      "evidence": "The document presents data on the impact of MYFEMBREE on daily activities and pain relief",
      "position": 0,
      "objective": "Highlight the need for effective treatment options",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}